-
1
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolmide for glioblastoma
-
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolmide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
-
(2005)
N Engl J Med
, vol.352
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
Van Den Bent, M.J.3
-
2
-
-
0027516695
-
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
-
Fine H, Dear K, Loeffler J, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 7181: 2585-2597.
-
(1993)
Cancer
, vol.7181
, pp. 2585-2597
-
-
Fine, H.1
Dear, K.2
Loeffler, J.3
-
3
-
-
33947533746
-
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
-
Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007; 68: 688-690.
-
(2007)
Neurology
, vol.68
, pp. 688-690
-
-
Hau, P.1
Koch, D.2
Hundsberger, T.3
-
4
-
-
0033897173
-
A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme in first relapse
-
Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme in first relapse. Br J Cancer. 2000; 83: 588-593.
-
(2000)
Br J Cancer
, vol.83
, pp. 588-593
-
-
Yung, W.K.A.1
Albright, R.E.2
Olson, J.3
-
5
-
-
55749094160
-
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The "rescue" approach
-
Perry JR, Rizek P, Cashman R, Morrison M, Morrison T,. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008; 113: 2152-2157.
-
(2008)
Cancer
, vol.113
, pp. 2152-2157
-
-
Perry, J.R.1
Rizek, P.2
Cashman, R.3
Morrison, M.4
Morrison, T.5
-
6
-
-
77951648272
-
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study
-
Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28: 2051-2057.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2051-2057
-
-
Perry, J.R.1
Bélanger, K.2
Mason, W.P.3
-
7
-
-
34548213721
-
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
-
Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25: 3357-3361.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3357-3361
-
-
Wick, A.1
Felsberg, J.2
Steinbach, J.P.3
-
9
-
-
0034050541
-
Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
-
Prendergast GC,. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol. 2000; 12: 166-173.
-
(2000)
Curr Opin Cell Biol
, vol.12
, pp. 166-173
-
-
Prendergast, G.C.1
-
10
-
-
0033539952
-
Growth inhibition of astrocytoma cells by farnesyltransferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects
-
Feldkamp MM, Lau N, Guha A,. Growth inhibition of astrocytoma cells by farnesyltransferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects. Oncogene. 1999; 18: 7514-7526.
-
(1999)
Oncogene
, vol.18
, pp. 7514-7526
-
-
Feldkamp, M.M.1
Lau, N.2
Guha, A.3
-
11
-
-
0034232138
-
Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336
-
Glass TL, Liu TJ, Yung WK,. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol. 2000; 2: 151-158.
-
(2000)
Neuro Oncol
, vol.2
, pp. 151-158
-
-
Glass, T.L.1
Liu, T.J.2
Yung, W.K.3
-
12
-
-
0025281789
-
Response criteria for phase II studies of supratentorial malignant glioma
-
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1277-1280
-
-
Macdonald, D.R.1
Cascino, T.L.2
Schold Jr., S.C.3
Cairncross, J.G.4
-
13
-
-
0032767387
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
-
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17: 2572-2578.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2572-2578
-
-
Wong, E.T.1
Hess, K.R.2
Gleason, M.J.3
-
14
-
-
33747058029
-
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study
-
Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006; 24: 3651-3656.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3651-3656
-
-
Cloughesy, T.F.1
Wen, P.Y.2
Robins, H.I.3
-
15
-
-
0032704708
-
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
-
Rowinsky EK, Windle JJ, Von Hoff DD,. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17: 3631-3652.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3631-3652
-
-
Rowinsky, E.K.1
Windle, J.J.2
Von Hoff, D.D.3
-
16
-
-
82955212823
-
A phase i trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
-
Desjardins A, Reardon DA, Peters KB, et al. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol. 2011; 105: 601-606.
-
(2011)
J Neurooncol
, vol.105
, pp. 601-606
-
-
Desjardins, A.1
Reardon, D.A.2
Peters, K.B.3
-
17
-
-
80052710752
-
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas
-
Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011; 104: 179-189.
-
(2011)
J Neurooncol
, vol.104
, pp. 179-189
-
-
Chaponis, D.1
Barnes, J.W.2
Dellagatta, J.L.3
-
18
-
-
3543148964
-
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
-
de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ,. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004; 63: 535-537.
-
(2004)
Neurology
, vol.63
, pp. 535-537
-
-
De Wit, M.C.1
De Bruin, H.G.2
Eijkenboom, W.3
Sillevis Smitt, P.A.4
Van Den Bent, M.J.5
-
19
-
-
0035990832
-
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
-
Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002; 13: 1067-1071.
-
(2002)
Ann Oncol
, vol.13
, pp. 1067-1071
-
-
Sharma, S.1
Kemeny, N.2
Kelsen, D.P.3
-
20
-
-
67749135818
-
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck
-
Hanrahan EO, Kies MS, Glisson BS, et al. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009; 32: 274-279.
-
(2009)
Am J Clin Oncol
, vol.32
, pp. 274-279
-
-
Hanrahan, E.O.1
Kies, M.S.2
Glisson, B.S.3
-
21
-
-
84862840384
-
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
-
Meier W, du Bois A, Rau J, et al. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol. 2012; 126: 236-240.
-
(2012)
Gynecol Oncol
, vol.126
, pp. 236-240
-
-
Meier, W.1
Du Bois, A.2
Rau, J.3
|